| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Gefitinib |
| Brand | Iressa® |
| Indication | For the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR. |
| Assessment Process | |
| Full pharmacoeconomic assessment commissioned by HSE | 16/06/2010 |
| NCPE assessment completed | 05/11/2020 |
We do not recommend the reimbursement of gefitinib for first line therapy on the High Tech Drug Scheme. However, it may be considered for second line therapy.